Monash University
Iconovo's oxytocin treatment in phase I clinical trial
Postpartum hemorrhage is the leading cause of maternal mortality globally, particularly in developing countries. Monash University collaborates with Iconovo to develop...
Iconovo begins 2023 with negotiations for ICOpre
Iconovo starts the new year with confidence after a...
Iconovo aims for new customer agreements in 2022
Iconovo
Iconovo's CEO looks back on an eventful 2021
In 2021, inhalation company Iconovo has managed to row in...
Iconovo's CEO on analysts' future forecasts
Iconovo is making progress in the company's seven ongoing customer projects...
Iconovo looks to the USA where it now meets quality requirements
One of Iconovo's goals is to launch future...
Iconovo aims high in its business goals
Last week, Iconovo communicated its financial operating targets for...
First approved patent in the US for Iconovo's ICOone
ICOone is Iconovo's single-dose inhaler for simple and cost-effective...
Iconovo ended 2020 with good sales figures
Last week, Iconovo published its fourth...
Iconovo's CEO comments on the year-end report
Inhalation company Iconovo has today published its financial report for 2020, which...
Major progress for Iconovo's major investment ICOpre
Iconovo recently filed the first two patent applications...
Iconovo aims for ambitious goals in 2021
Yesterday, Iconovo presented its business goals for 2021,...